$12.14
Insights on Neogen Corp
Revenue is down for the last 2 quarters, 229.62M → 228.81M (in $), with an average decrease of 0.4% per quarter
Netprofit is up for the last 2 quarters, -3.48M → -2.02M (in $), with an average increase of 72.5% per quarter
In the last 1 year, Iqvia Holdings Inc. has given 12.1% return, outperforming this stock by 37.6%
In the last 3 years, Thermo Fisher Scientific, Inc. has given 5.4% return, outperforming this stock by 79.8%
1.89%
Downside
Day's Volatility :4.76%
Upside
2.92%
3.29%
Downside
52 Weeks Volatility :51.29%
Upside
49.63%
Period | Neogen Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -28.55% | -0.7% | 0.0% |
6 Months | -20.86% | 6.6% | 0.0% |
1 Year | -25.48% | 3.7% | -1.5% |
3 Years | -74.57% | 14.0% | -21.8% |
Market Capitalization | 2.6B |
Book Value | $14.53 |
Earnings Per Share (EPS) | 0.02 |
PE Ratio | 608.0 |
PEG Ratio | 0.66 |
Wall Street Target Price | 17.0 |
Profit Margin | 0.17% |
Operating Margin TTM | 5.26% |
Return On Assets TTM | 1.79% |
Return On Equity TTM | 0.05% |
Revenue TTM | 929.2M |
Revenue Per Share TTM | 4.29 |
Quarterly Revenue Growth YOY | 4.8% |
Gross Profit TTM | 409.2M |
EBITDA | 246.8M |
Diluted Eps TTM | 0.02 |
Quarterly Earnings Growth YOY | -0.86 |
EPS Estimate Current Year | 0.46 |
EPS Estimate Next Year | 0.55 |
EPS Estimate Current Quarter | 0.14 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 40.03%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 402.3M | ↑ 11.24% |
Net Income | 63.1M | ↑ 44.19% |
Net Profit Margin | 15.7% | ↑ 3.59% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 414.2M | ↑ 2.97% |
Net Income | 60.2M | ↓ 4.7% |
Net Profit Margin | 14.53% | ↓ 1.17% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 418.2M | ↑ 0.96% |
Net Income | 59.5M | ↓ 1.16% |
Net Profit Margin | 14.22% | ↓ 0.31% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 468.5M | ↑ 12.03% |
Net Income | 60.9M | ↑ 2.37% |
Net Profit Margin | 13.0% | ↓ 1.22% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 527.2M | ↑ 12.53% |
Net Income | 48.3M | ↓ 20.65% |
Net Profit Margin | 9.16% | ↓ 3.84% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 822.4M | ↑ 56.01% |
Net Income | -22.9M | ↓ 147.34% |
Net Profit Margin | -2.78% | ↓ 11.94% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 230.0M | ↑ 73.81% |
Net Income | -41.8M | ↓ 903.24% |
Net Profit Margin | -18.19% | ↓ 22.13% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 218.3M | ↓ 5.12% |
Net Income | 8.2M | ↓ 119.57% |
Net Profit Margin | 3.75% | ↑ 21.94% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 241.8M | ↑ 10.79% |
Net Income | 5.6M | ↓ 31.97% |
Net Profit Margin | 2.3% | ↓ 1.45% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 229.0M | ↓ 5.3% |
Net Income | 1.5M | ↓ 73.03% |
Net Profit Margin | 0.66% | ↓ 1.64% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 229.6M | ↑ 0.28% |
Net Income | -3.5M | ↓ 332.0% |
Net Profit Margin | -1.52% | ↓ 2.18% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 228.8M | ↓ 0.36% |
Net Income | -2.0M | ↓ 42.01% |
Net Profit Margin | -0.88% | ↑ 0.64% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 618.0M | ↑ 16.96% |
Total Liabilities | 57.8M | ↑ 2.09% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 695.7M | ↑ 12.58% |
Total Liabilities | 57.8M | ↑ 0.01% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 797.2M | ↑ 14.58% |
Total Liabilities | 72.0M | ↑ 24.49% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 920.2M | ↑ 15.43% |
Total Liabilities | 79.8M | ↑ 10.85% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 992.9M | ↑ 7.9% |
Total Liabilities | 105.6M | ↑ 32.25% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 4.6B | ↑ 358.69% |
Total Liabilities | 1.4B | ↑ 1245.47% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 4.6B | ↑ 366.64% |
Total Liabilities | 1.5B | ↑ 1454.09% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 4.5B | ↓ 1.15% |
Total Liabilities | 1.4B | ↓ 4.92% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 4.6B | ↑ 1.01% |
Total Liabilities | 1.4B | ↑ 2.68% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 4.6B | ↑ 0.15% |
Total Liabilities | 1.4B | ↓ 0.37% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 4.6B | ↑ 0.91% |
Total Liabilities | 1.5B | ↑ 2.82% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 4.6B | ↓ 0.43% |
Total Liabilities | 1.4B | ↓ 1.27% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 69.1M | ↑ 14.69% |
Investing Cash Flow | -83.1M | ↑ 33.71% |
Financing Cash Flow | 22.8M | ↓ 8.9% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 63.8M | ↓ 7.65% |
Investing Cash Flow | -119.1M | ↑ 43.41% |
Financing Cash Flow | 13.9M | ↓ 39.14% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 85.9M | ↑ 34.52% |
Investing Cash Flow | -88.8M | ↓ 25.48% |
Financing Cash Flow | 29.4M | ↑ 111.56% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 81.1M | ↓ 5.58% |
Investing Cash Flow | -105.6M | ↑ 18.9% |
Financing Cash Flow | 33.5M | ↑ 14.08% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 68.0M | ↓ 16.09% |
Investing Cash Flow | -97.2M | ↓ 7.9% |
Financing Cash Flow | 6.8M | ↓ 79.69% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 41.0M | ↓ 39.7% |
Investing Cash Flow | 201.0M | ↓ 306.77% |
Financing Cash Flow | -118.1M | ↓ 1833.17% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -18.7M | ↑ 32.4% |
Investing Cash Flow | 93.0M | ↑ 13.92% |
Financing Cash Flow | -79.3M | ↓ 8858.12% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -17.1M | ↓ 8.85% |
Investing Cash Flow | 6.9M | ↓ 92.61% |
Financing Cash Flow | -40.0M | ↓ 49.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 91.0M | ↓ 632.93% |
Investing Cash Flow | 6.9M | ↑ 0.0% |
Financing Cash Flow | 252.0K | ↓ 100.63% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 23.0M | ↓ 74.71% |
Investing Cash Flow | -8.7M | ↓ 226.29% |
Financing Cash Flow | 1.1M | ↑ 321.43% |
Sell
Neutral
Buy
Neogen Corp is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Neogen Corp | -19.44% | -20.86% | -25.48% | -74.57% | -57.22% |
Idexx Laboratories, Inc. | -9.73% | 12.44% | -0.8% | -9.52% | 118.88% |
Agilent Technologies Inc. | -7.9% | 23.88% | -3.2% | 0.79% | 76.64% |
Thermo Fisher Scientific, Inc. | -5.65% | 17.12% | -6.43% | 12.22% | 110.66% |
Danaher Corp. | -4.8% | 16.89% | -6.54% | -1.07% | 88.84% |
Iqvia Holdings Inc. | -10.49% | 20.27% | 12.09% | 5.1% | 70.85% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Neogen Corp | 608.0 | 608.0 | 0.66 | 0.46 | 0.0 | 0.02 | NA | 14.53 |
Idexx Laboratories, Inc. | 48.76 | 48.76 | 4.75 | 11.13 | 0.81 | 0.23 | NA | 17.88 |
Agilent Technologies Inc. | 33.53 | 33.53 | 2.7 | 5.5 | 0.21 | 0.08 | 0.01 | 21.12 |
Thermo Fisher Scientific, Inc. | 35.85 | 35.85 | 2.81 | 21.56 | 0.13 | 0.05 | 0.0 | 120.87 |
Danaher Corp. | 42.54 | 42.54 | 3.13 | 7.62 | 0.08 | 0.04 | 0.0 | 72.36 |
Iqvia Holdings Inc. | 31.74 | 31.74 | 1.33 | 11.11 | 0.23 | 0.05 | NA | 33.67 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Neogen Corp | Buy | $2.6B | -57.22% | 608.0 | 0.17% |
Idexx Laboratories, Inc. | Buy | $40.7B | 118.88% | 48.76 | 23.08% |
Agilent Technologies Inc. | Buy | $41.1B | 76.64% | 33.53 | 18.35% |
Thermo Fisher Scientific, Inc. | Buy | $211.7B | 110.66% | 35.85 | 13.99% |
Danaher Corp. | Buy | $178.0B | 88.84% | 42.54 | 19.94% |
Iqvia Holdings Inc. | Buy | $42.1B | 70.85% | 31.74 | 9.06% |
BlackRock Inc
Vanguard Group Inc
NORGES BANK
Wasatch Advisors Inc.
Select Equity Group LP
Baillie Gifford & Co Limited.
neogen corporation develops and markets products dedicated to food and animal safety. the company’s food safety division markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. neogen’s animal safety division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants and rodenticides.
Organization | Neogen Corp |
Employees | 2640 |
CEO | Mr. John Edward Adent |
Industry | Health Technology |
Vanguard Ultra Short Bond Et
$12.14
-0.16%
Surgery Partners Inc
$12.14
-0.16%
Sl Green Realty Corp.
$12.14
-0.16%
Goldman Sachs Activebeta Int
$12.14
-0.16%
Allegro Microsystems, Inc.
$12.14
-0.16%
Cleanspark Inc
$12.14
-0.16%
Chart Industries Inc.
$12.14
-0.16%
Agree Realty Corp
$12.14
-0.16%
Joby Aviation Inc
$12.14
-0.16%